(Getty Images)

UP-TO-DATE

Tinder taps AI that can analyze your camera roll to find better matches

As Tinder’s paid subscriber count dwindles, Match Group wants to fight “swipe fatigue” with new features.

11/6/25 10:34AM

If you’ve grappled with describing yourself in an online dating profile beyond liking dogs, food, and walks on the beach, don’t worry: an AI matchmaker might soon be able to ascertain your interests for you.

As long as you give it access to all of your personal photos, of course.

In its weaker-than-expected third-quarter earnings on Tuesday, Match Group emphasized accelerating product innovation as a way to spark sales growth at its crown jewel, Tinder. Indeed, the swipe-centric dating app saw paid subscribers fall by 7% year over year in Q3 — marking nine consecutive quarters of payer numbers declining.

One way Match plans to win over free users is by providing Tinder payers with more compatible matches, thus combating so-called “swipe fatigue.”

How? A new AI-powered “Chemistry” feature that will learn about users’ personalities via a series of questions... and, with permission, look through their camera rolls for further clues about their hobbies, likes, and dislikes.

Cupid’s bot

According to CEO Spencer Rascoff, the company intends to make the “interactive matching feature” a “major pillar of Tinder’s upcoming 2026 product experience” — with Match’s Q4 guidance outlining a $14 million hit to the app’s direct revenue from user experience testing.

(And, if a Match-made bot scanning your private pictures feels invasive, fret not! It won’t be the only one: Meta launched a similar edit-suggesting AI feature only last month, alongside a slew of other apps that use the tech and request access to photos.)

Total swipeout

This isn’t the first time that Tinder has trialed unconventional courting methods to return to growth, but it may be the most crucial. While Match Group’s Hinge remains a rare bright spot in the online dating space, rival app Bumble reported paying users tumbling 18% in Q3 on Wednesday.

Perhaps swipe-weary singles are showing dating apps the door — or perhaps people are just no longer willing to pay for them. Earlier this week, Meta released figures for Facebook Dating. Surprisingly, the free-to-use, social-linked platform has 21.5 million daily active users, and even more surprising is that nearly 1.8 million of these are 18 to 29 years old.

J. Edward Moreno

19h

Hims built a boundary-pushing health business. Now the legal risks are catching up.

Hims is close to trading as if it never began selling GLP-1s.

Nate Becker2/7/26

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration.

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims & Hers Comms on X

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

J. Edward Moreno2/6/26

$1.3M

Max Knoblauch2/6/26

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26